Copy that FBG, we both have been here for a ridiculouly long time and let's hope the endgame is in sight. I do differ with you regarding our ultimate value but am in full agreement that this needs to transition to more capable hands. Enough is enough, this technology is so much more than a company our size can manage to market and we have already seen DOC's missteps attempting to grow into a pharma in our own right; I see our current valuation as a judgement on management's record getting our science to market rather than a valuation of our technology. Hopefully Lombardo validates our judgement to hang in here all these years.
News 
Market Data 
Discover 
